Inimmune Corporation

3:00 PM - 3:15 PM (PDT), Monday, June 13, 2022
Inimmune is harnessing the human immune system to create next generation immunotherapeutics for the treatment of allergy, infectious disease, autoimmunity and cancer. Our team has over 20 years of expertise in discovering and developing safe and effective immunomodulators that can be used for the treatment of a wide array of diseases and disorders. We have a proven track record of innovation, intellectual property generation, effective collaboration and sourcing of external funding to drive our immune therapies forward.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
INI-4001 for immuno-oncology, INI-2004 for seasonal allergic rhinits
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
President & CEO
Inimmune Corporation